DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
19.97
-1.03 (-4.90%)
At close: Apr 21, 2026, 4:00 PM EDT
19.70
-0.27 (-1.35%)
After-hours: Apr 21, 2026, 5:20 PM EDT
DBV Technologies Revenue
In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth. DBV Technologies had revenue of $645.00K in the quarter ending December 31, 2025, with 26.22% growth.
Revenue (ttm)
$5.64M
Revenue Growth
+35.80%
P/S Ratio
211.72
Revenue / Employee
$48,171
Employees
117
Market Cap
1.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | -2.00M | -11.96% |
| Dec 31, 2018 | 16.71M | 2.42M | 16.90% |
| Dec 31, 2017 | 14.29M | 4.73M | 49.50% |
| Dec 31, 2016 | 9.56M | 2.86M | 42.76% |
| Dec 31, 2015 | 6.70M | 933.42K | 16.20% |
| Dec 31, 2014 | 5.76M | 498.99K | 9.48% |
| Dec 31, 2013 | 5.26M | 1.60M | 43.69% |
| Dec 31, 2012 | 3.66M | 1.24M | 51.01% |
| Dec 31, 2011 | 2.43M | 143.68K | 6.30% |
| Dec 31, 2010 | 2.28M | 734.19K | 47.44% |
| Dec 31, 2009 | 1.55M | 93.10K | 6.40% |
| Dec 31, 2008 | 1.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 376.13M |
| AbCellera Biologics | 75.13M |
| Septerna | 45.95M |
| EyePoint | 31.37M |
| Zenas BioPharma | 10.00M |
| Inhibrx Biosciences | 1.30M |
DBVT News
- 19 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 - GlobeNewsWire
- 26 days ago - DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 26 days ago - DBV Technologies Reports Full Year 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - GlobeNewsWire
- 6 weeks ago - DBV Technologies to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 7 weeks ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 - GlobeNewsWire